Importantly, CD68+ sublining macrophages, a synovial biomarker with a high sensitivity in selecting effective RA therapies in an early stage of drug development, is significantly reduced in the synovia of celastrol-treated rats. The gene discussed is CD68; the disease is rheumatoid arthritis.